Navigation Links
Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases
Date:11/17/2008

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB, reported positive additional interim results from its ongoing phase I/II clinical study of its therapeutic DNA vaccine against hepatitis C virus (HCV). This vaccine is being delivered using Inovio’s electroporation-based DNA delivery system. In the third and highest dose cohort of the study, two of three subjects demonstrated reductions in viral load of 93% and 99.7%. Previously reported middle dose cohort results demonstrated an 87% and 98% reduction in HCV in two of three subjects, while no anti-viral effect was observed in the low dose cohort. No safety issues have been noted to date in the trial. These data suggest a potential dose response of the vaccine and support the inclusion of three additional subjects in the high dose cohort.

SAN DIEGO (Business Wire EON) November 17, 2008 -- These data where presented by Dr. Matti Sllberg of Tripep at the recent American Association for the Study of Liver Diseases meeting held in San Francisco.

Avtar Dhillon, MD, Inovio's president and CEO, stated: "We continue to be encouraged by the data flowing out of the ChronVac-C study. This promising DNA vaccine candidate, in which Inovio has an ownership position, is one of the more advanced clinical vaccine candidates in the HCV field. ChronVac-C was designed to play a role as a first-line therapy or as an adjunct to existing therapies."

About ChronVac-C

ChronVac-C is a therapeutic DNA-based vaccine given to individuals already infected with the hepatitis C virus with the aim of clearing the infection from the liver by boosting the body's immune response against the virus. Inovio's electroporation technology is being used to deliver the vaccine and is intended to enhance the
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
2. Roche Receives FDA Approval for Hepatitis C Viral Load Test on Its Fully Automated Real-Time PCR Platform
3. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
4. Why Are Some Veterans Who Are Coinfected With Hepatitis C and HIV More Likely to Be Treated for HCV Than Others?
5. Hepatitis C treatment is cost-effective for the US prison population
6. Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
7. Majority of children vaccinated against hepatitis B not at increased risk of MS
8. How to select anti-hepatitis B virus agents for drug-resistance patients?
9. The prevalence of hepatitis B virus infection in inflammatory bowel disease patients
10. A potential approach to treatment of hepatitis B virus infection
11. New approach, old drug show promise against hepatitis C, Stanford research shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% :  Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases 
(Date:3/31/2015)... TX (PRWEB) March 31, 2015 One of the ... be a visit to Mount Kilauea on the big island. ... few places where you can see molten lava slowly oozing at ... on earth. , One place you would never expect ... the flat, arid terrain of Mission, Texas -- until now. , ...
(Date:3/31/2015)... Indosoft, Inc., developers of contact center ... of SIP over TCP configuration for all SIP devices in ... full contact center ACD (Automatic Call Distributor) system ... over TCP support to all SIP devices gives users an ... of Voice over IP (VoIP) has primarily involved User Datagram ...
(Date:3/31/2015)... 2015 National Adaptive Sports Month ... psychological benefits of participating in adaptive sports activities, ... sports athletes that adapt, believe and compete each ... inclusive fitness and inclusive athletics in our schools, ... adaptive sports and advocate for an increase in ...
(Date:3/31/2015)... 2015 Array Health , a ... announced that Lance Hood, Senior Director of Marketing, will ... Forum on April 1, 2015. The session, co-presented with ... address how employers can streamline and simplify the private ... “ Optimizing Employee and Employer Needs in a Private ...
(Date:3/31/2015)... 2015 With intravenous (IV) infusion therapy, ... catheter. Patients, typically, are prescribed IV infusion therapy when ... are no longer effective. Illness often leads to ... with electrolyte imbalances. Infusion therapy benefits the patient’s ... to treating dehydration, IV infusion therapy can be used ...
Breaking Medicine News(10 mins):Health News:Rare Volcano Constructed inside Gold’s Gym in Mission, Texas 2Health News:Rare Volcano Constructed inside Gold’s Gym in Mission, Texas 3Health News:Indosoft extends SIP over TCP support to User Extensions in its Q-Suite 5.9 Call Center Software 2Health News:April is National Adaptive Sports Month 2Health News:April is National Adaptive Sports Month 3Health News:Array Health’s Senior Director of Marketing to Co-Present with Benaissance at The Institute for HealthCare Consumerism Private Exchange Forum 2Health News:Intravenous Infusion Therapy Now Available at Urgent Care of Texas Centers; Hospital-Level Care in an Outpatient Setting. 2
... Oct. 16 Dr. Sanjay Gupta, CNN chief medical correspondent, ... College "Compelling Conversations" speaker series. Gupta will ... A300 auditorium. , A leader in the national ... CNN television shows "American Morning" and "House Call with Sanjay ...
... the Yerkes National Primate Research Center, Emory University, ... at the Society for Neuroscience,s 39th annual meeting ... is a representation of the neuroscience research Yerkes ... ongoing research and scientific resources available at the ...
... issued to 17 centers for lax reporting of procedure-related ... -- The percentage of patients who experience serious quality-of-life ... the U.S. Food and Drug Administration, which has also ... that weren,t properly reporting problems with the procedure. , ...
... are boosting rates to double the national average, researchers say ... percent of people in Milwaukee,s poorest neighborhoods smoke -- more ... a pack of cigarettes even while most of the households ... troubling is the fact that a large number of these ...
... Oct. 16 When Royal Caribbean International officially names ... most revolutionary cruise ship - on Nov. 30, 2009 from ... cruise line will be doing more than making wishes come ... across the country through the Make-A-Wish Foundation. Royal Caribbean will ...
... HARRISBURG, Pa., Oct. 16 Secretary of Aging John ... Pennsylvania to create and donate ornaments for the Christmas ... hand-made ornaments will showcase the talents and creativity of ... by members of senior centers have become a holiday ...
Cached Medicine News:Health News:CNN Medical Correspondent Sanjay Gupta to Speak at Bunker Hill Community College 2Health News:Yerkes researchers present at 39th Annual Society for Neuroscience Conference 2Health News:Yerkes researchers present at 39th Annual Society for Neuroscience Conference 3Health News:Yerkes researchers present at 39th Annual Society for Neuroscience Conference 4Health News:Yerkes researchers present at 39th Annual Society for Neuroscience Conference 5Health News:New FDA Study Seeks Feedback on Lasik Surgery 2Health News:Smoking Keeps Its Grip on Urban Poor 2Health News:Smoking Keeps Its Grip on Urban Poor 3Health News:Royal Caribbean to Grant Wishes Onboard Oasis Of The Seas 2Health News:Royal Caribbean to Grant Wishes Onboard Oasis Of The Seas 3Health News:Royal Caribbean to Grant Wishes Onboard Oasis Of The Seas 4
(Date:3/31/2015)... March 31, 2015 The Medical Letter ... in the American Medical Group Association,s "High Performing ... AMGA,s "High Performing Health" production is an ... the nation,s healthcare system in delivering better care ... along with other leading organizations in the healthcare ...
(Date:3/31/2015)... 2015 According to a ... Instrumentation Market (Chromatography, Electrophoresis, DNA Sequencer, PCR, Microplate Reader, ... Hood, Centrifuge) - Global Forecast to 2019", published ... Instrumentation Market is expected to reach $48.84 Billion ... to 2019. Browse   9 ...
(Date:3/31/2015)... March 31, 2015 Ryan & Maniskas, ... of directors of Hyperion Therapeutics, Inc. ("Hyperion" or the ... fiduciary duty and other violations of law related to ... Pharma plc in a transaction valued at approximately $1.1 ... and would like to learn more about this class ...
Breaking Medicine Technology:AMGA's High Performing Health News Program Features The Medical Letter 2Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 2Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 3Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 4Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 5Ryan & Maniskas, LLP Announces Investigation of Hyperion Therapeutics, Inc. 2
... presented at Israel Society of Nephrology Conference ... months from single treatment - Data continue to ... expensive injections MISGAV, Israel and LONDON, March 27 ... latest, encouraging results of the Company,s ongoing EPODURE Biopump ...
... of Clinical Lipidology publishes largest study comparing cancer ... using FDA database -BOSTON, March 25 A ... ezetimibe mono and ezetimibe/simvastatin combination treatments, compared to ... The study, conducted by Tufts Medical Center ...
Cached Medicine Technology:Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 2Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 3Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 4Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows 2
... is the isotope used in Theraseed ... of an uncooked grain of rice, ... radiation. Within just three months it ... energy and has lost almost all ...
... complete anterior chamber angle viewing with ... for easy handling and stability. Choice ... diameter contact surface allows static or ... multi-layer polymer coating protects mirrors and ...
... High Refractive Index glass provides ... in contact with the mirrors. Total ... or loss by a mirror coating ... High resolution image of the anterior ...
Two opposing 62 mirrors provide a complete view of the anterior chamber angle with only a 180 lens rotation. Methylcellulose and no methylcellulose designs available....
Medicine Products: